Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
GT.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
XBB.1.5.87NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBB.1.5.87NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
XAPNUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XAPNUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BE.1.4.3NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BE.1.4.3NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
XBB.1.11NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBB.1.11NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BQ.1.1.68NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BQ.1.1.68NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BF.7.26NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BF.7.26NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BR.1.2NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BR.1.2NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BQ.1.1.25NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BQ.1.1.25NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BQ.1.1.51NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BQ.1.1.51NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
CA.3NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
CA.3NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BN.5NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BN.5NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BE.8NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BE.8NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BF.7.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BF.7.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BH.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BH.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BQ.1.19NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BQ.1.19NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BF.3.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BF.3.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BA.5.2.4NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BA.5.2.4NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BA.5.1.19NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BA.5.1.19NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BF.7.3NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BF.7.3NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BA.2.75.4NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BA.2.75.4NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
B.1.160.8NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.160.8NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
XBB.2.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBB.2.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BE.4.1.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BE.4.1.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
B.1.177.12NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.177.12NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BA.5.2.41NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used